Rate My Professor Eynav Klechevsky

Klechevsky's research addresses fundamental and translational questions in human immunology, particularly the functional specialization of DC subtypes, their co-receptor and cytokine production, T cell skewing and differentiation, and roles in disease. Using human patient samples and models, her lab has identified a new inflammatory DC type and mechanisms to enhance immune treatments for cancer and autoimmunity, aiming to create new vaccines and immunotherapies. She has received major awards including an RO1 grant from the National Cancer Institute (2020) for work on DCs in melanoma, an RO1 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (2019) for skin DCs in psoriasis, an R21 NIH/NIBIB Trailblazer Award (2018) in collaboration with Amit Pathak, and a Translational Grant from the National Psoriasis Foundation (2017). Klechevsky chairs the 18th International Workshop on Langerhans Cells (LC2025). Key publications encompass "Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells" (Immunity, 2008), "Electrophilic properties of itaconate and derivatives regulate the IκBζ–ATF3 inflammatory axis" (Nature, 2018), "Dendritic cell subsets in health and disease" (Immunological Reviews, 2007), "CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses" (Science, 2023), and "Dendritic cells function beyond antigen presentation" (Cancer Cell, 2025). Her research has amassed over 3,300 citations, significantly impacting dendritic cell research and immunotherapy development.